NewAmsterdam Pharma
Developing obicetrapib and other therapies for cardiovascular disease and lipid-related conditions
Highlights
- New on EvolcAdded 2026-11-13
About NewAmsterdam Pharma
NewAmsterdam Pharma is developing treatments for cardiovascular disease and other lipid-related conditions. Its investigational asset obicetrapib is a selective cholesteryl ester transfer protein (CETP) inhibitor intended to lower LDL cholesterol and reduce cardiovascular risk.
The company was co-founded by lipidologist Professor John Kastelein and venture capital firm Forbion. It completed a Series A funding round in 2020 and debuted on Nasdaq in 2022; it licensed European commercialization rights for obicetrapib to the Menarini Group.
Product: Drug development focused on obicetrapib, an investigational CETP inhibitor for cardiovascular and lipid-related conditions.
Jobs at NewAmsterdam Pharma
More biotech & pharma companies
Octant Bio
Biotechnology company developing small-molecule medicines for patients with genetic and other serious diseasesNew on EvolcOlema Oncology
Clinical-stage biopharmaceutical developing novel therapies for patients with metastatic breast canceronepot
Automated custom small-molecule synthesis for researchers and organizations developing chemical compoundsYoung companyNew on EvolcOssium Health
Bone marrow-derived cell therapies for healthcare providers and life science companiesNew on EvolcOxfordbiotherapeutics
Develops antibody-based cancer therapies and target-discovery services for oncology partners and patientsRemote-friendlySalary transparentParabilis Medicines
Develops peptide-based medicines for patients with serious diseases, including cancerSalary transparent
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.